Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average recommendation of “Hold” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $3.8333.

Several research analysts have issued reports on SGMO shares. Barclays reiterated an “equal weight” rating and issued a $1.00 price target (down previously from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Wall Street Zen lowered Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, September 4th.

Sangamo Therapeutics Stock Up 3.8%

Shares of NASDAQ SGMO opened at $0.45 on Tuesday. The firm has a market cap of $150.21 million, a PE ratio of -1.01 and a beta of 1.41. The company’s fifty day simple moving average is $0.52 and its 200 day simple moving average is $0.54. Sangamo Therapeutics has a 12-month low of $0.38 and a 12-month high of $2.73.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.08). The company had revenue of $0.58 million for the quarter, compared to analyst estimates of $34.40 million. Sangamo Therapeutics had a negative net margin of 331.28% and a negative return on equity of 813.95%. On average, equities analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several large investors have recently added to or reduced their stakes in SGMO. Invesco Ltd. boosted its stake in Sangamo Therapeutics by 82.8% during the 1st quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 219,253 shares during the last quarter. OMERS ADMINISTRATION Corp lifted its holdings in shares of Sangamo Therapeutics by 93.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 207,800 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 100,500 shares in the last quarter. Caption Management LLC purchased a new position in shares of Sangamo Therapeutics during the first quarter valued at approximately $37,000. Jacobs Levy Equity Management Inc. grew its holdings in Sangamo Therapeutics by 74.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 555,323 shares in the last quarter. Finally, Wealth Management Associates Inc. raised its position in Sangamo Therapeutics by 213.7% in the 1st quarter. Wealth Management Associates Inc. now owns 228,400 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 155,600 shares during the last quarter. Institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.